World J Gastrointest Endosc. Jan 16, 2026; 18(1): 112920 Published online Jan 16, 2026. doi: 10.4253/wjge.v18.i1.112920
Purastat therapy for bleeding radiation proctopathy
Jervoise Andreyev
Jervoise Andreyev, Department of Gastroenterology, Lincoln County Hospital, Lincoln LN2 5QY, Lincolnshire, United Kingdom
Author contributions: Andreyev J contributed to designed, conducted, analysed and wrote the study.
Conflict-of-interest statement: The author declare that he received Purastat without charge from the manufacturers to treat the patients enrolled in this study but has no other conflict of interest to disclose.
Corresponding author: Jervoise Andreyev, Consultant, Department of Gastroenterology, Lincoln County Hospital, Greetwell Road, Lincoln LN2 5QY, Lincolnshire, United Kingdom. jervoiseandreyev@gmail.com
Received: August 11, 2025 Revised: August 31, 2025 Accepted: December 19, 2025 Published online: January 16, 2026 Processing time: 159 Days and 6.2 Hours
Abstract
There are limited data as to the effectiveness of Purastat to treat bleeding radiation proctopathy. We present prospectively collected data from a consecutive series of 11 patients with severely symptomatic bleeding radiation proctopathy treated with Purastat. Bleeding reduced after treatment and became very minor or occasional or stopped completely, in all patients after a median of 3 treatments. Two thirds of patents improved with each treatment, one third needed two or more treatments before bleeding reduced. Nuisance scores before treatment were a median 8.5/10 and fell to 0.5/10 at last follow up. The improvement seen was sustained over time.
Core Tip: New data on the effectiveness of Purastat. There are limited data as to the effectiveness of Purastat to treat bleeding radiation proctopathy. Purastat reduced bleeding and improved nuisance scores in 11 patients with severely symptomatic bleeding radiation proctopathy.
